These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 19955298

  • 1. Sevelamer carbonate.
    Barna MM, Kapoian T, O'Mara NB.
    Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
    [Abstract] [Full Text] [Related]

  • 2. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB, Shepler BM.
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [Abstract] [Full Text] [Related]

  • 3. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis.
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 5. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [Abstract] [Full Text] [Related]

  • 6. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
    Biggar P, Ketteler M.
    Expert Opin Pharmacother; 2010 Nov; 11(16):2739-50. PubMed ID: 20977406
    [Abstract] [Full Text] [Related]

  • 7. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y, Takami H, Tani M, Yamaguchi Y, Goto H, Goto Y, Goto Y, Shigematsu T.
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [Abstract] [Full Text] [Related]

  • 9. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D, Jachimiak B, Cieślak-Puchalska A, Pacanowska B, Zimoń T.
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [Abstract] [Full Text] [Related]

  • 10. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R, Dryja P, Łacina D, Króliczak V, Chrul S, Kacprzyk F.
    Wiad Lek; 2011 Apr; 64(1):9-14. PubMed ID: 21812357
    [Abstract] [Full Text] [Related]

  • 11. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM.
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [Abstract] [Full Text] [Related]

  • 13. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M, Bartko-Winters S, Bernard L, Fenton A, Hutchison C, Di Iorio B.
    J Med Econ; 2013 Jul; 16(6):744-55. PubMed ID: 23550810
    [Abstract] [Full Text] [Related]

  • 14. Sevelamer therapy for pediatric end-stage renal disease.
    Storms LE, Chicella MF, Dice JE.
    Pharmacotherapy; 2006 Mar; 26(3):410-3. PubMed ID: 16503722
    [Abstract] [Full Text] [Related]

  • 15. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M, Fukagawa M.
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [Abstract] [Full Text] [Related]

  • 17. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.
    Chow KM, Szeto CC, Kwan BC, Leung CB, Li PK.
    J Nephrol; 2007 Nov; 20(6):674-82. PubMed ID: 18046669
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
    Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R.
    Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
    [Abstract] [Full Text] [Related]

  • 19. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 Dec; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 20. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N, Lindholm B, Stenvinkel P.
    Semin Dial; 2008 Dec; 21(5):385-9. PubMed ID: 18573137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.